Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Respiratory Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Respiratory Infections
    Predicting Tuberculosis Outbreaks Based on the First 2 Cases - (DGNews)
    TopAbstracts in Respiratory Infections 06/23/2008 - (DGNews)
    TopAbstracts in Respiratory Infections 06/09/2008 - (DGNews)
    TopAbstracts in Respiratory Infections 05/26/2008 - (DGNews)
    Silver-Coated Endotracheal Tubes Reduce Rates of Ventilator-Associated Pneumonia: Presented at ATS - (DGDispatch)

    News archive

     Recent webcasts/CME - Respiratory Infections
      Pharmacological Management of Coughs and Colds
      Evaluation and Management of Pneumonia in Older Adults
      The Latest on Community-Acquired Pneumonia
      Principles of Treatment of CAP - Part 2: Implications of Antimicrobial Pharmocokinetics/Pharmocodynamics
      Principles of Treatment of CAP - Part I: Implications of Antimicrobial Resistance

      Webcasts/CME archive

       Recent cases - Respiratory Infections
        Coexistence of Primary Adenocarcinoma of the Lung and Tsukamurella Pneumonia: A Case Report and Review of the Literature
        Fatal Necrotizing Pneumonia Due to a Panton-Valentine Leukocidin Positive Community-Associated Methicillin-Sensitive Staphylococcus Aureus and Influenza Co-Infection: A Case Report
        Lessons from Mycobacterium Avium Complex-Associated Pneumonitis: A Case Report
        Malaise, Weight Loss, Pleuritic Chest Pain and Productive Cough: What is Your Call?
        Rapidly Progressive Bronchiolitis Obliterans Organising Pneumonia Presenting with Pneumothorax, Persistent Air Leak, Acute Respiratory Distress Syndrome and Multi-Organ Dysfunction: A Case Report

        Cases archive
          




        my personal edition > respiratory infections > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Are Antibiotics Being Used for Too Long?

        LONDON, UK -- June 9, 2006 -- Taking antibiotics for 3 days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7 to 10 days, finds a study in this week's British Medical Journal (BMJ). Shorter treatment can also help contain growing resistance rates.

        The study raises questions about the optimal duration of antibiotic therapy for common infections.

        Community acquired pneumonia is one of the most important indications for antibiotic prescriptions in hospitals. But a lack of evidence to support short course therapy means it has become accepted practice to continue treatment for days after symptoms have improved.

        Researchers in the Netherlands compared the effectiveness of discontinuing treatment with amoxicillin after 3 days or eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia.

        119 patients who substantially improved after the conventional three days' treatment with intravenous amoxicillin were randomly assigned to oral amoxicillin (63 patients) or placebo (56 patients) 3 times daily for 5 days. Patients were assessed at days 7, 10 (two days after treatment ended), 14, and 28.

        In the 3 day and eight day treatment groups, the clinical success rate at day 10 was 93% for both, and at day 28 was 90% compared with 88%. Both groups had similar resolution of symptoms, x-ray results, and length of hospital stay.

        These findings show that discontinuing amoxicillin treatment after three days is not inferior to discontinuing it after eight days in adults with mild to moderate-severe community acquired pneumonia who have substantially improved after an initial three days' treatment, say the authors.

        A shorter duration of treatment can also help to reduce overall antibiotic consumption and resistance rates for respiratory infections, they conclude.

        This study suggests that current guidelines recommending 7 to 10 days should be revised, says Dr. John Paul from the Royal Sussex County Hospital, in an accompanying commentary.

        Not only does the study yield strong evidence in favour of short course therapy for a subset of patients with community acquired pneumonia, but also shows how centres can cooperate to tackle longstanding areas of uncertainty in clinical microbiology and infectious diseases, he writes. Many other common clinical situations would repay the efforts of comparable approaches.


        REFERENCES:
        1. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised double blind study BMJ Volume 332 pp 1355-8.
        2. Commentary: What is the optimal duration of antibiotic therapy? BMJ Volume 332 pp 1358.


        SOURCE: British Medical Journal



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send